2,3-dimethoxy-5-methyl-6-decyl-1,4-benzoquinone and Friedreich Ataxia

2,3-dimethoxy-5-methyl-6-decyl-1,4-benzoquinone has been researched along with Friedreich Ataxia in 1 studies

2,3-dimethoxy-5-methyl-6-decyl-1,4-benzoquinone: ubiquinol analog
6-decylubiquinone : A member of the class of 1,4-benzoquinones that is 2,3-dimethoxybenzoquinone which has been substituted at positions 5 and 6 by decyl and methyl groups.

Friedreich Ataxia: An autosomal recessive disease, usually of childhood onset, characterized pathologically by degeneration of the spinocerebellar tracts, posterior columns, and to a lesser extent the corticospinal tracts. Clinical manifestations include GAIT ATAXIA, pes cavus, speech impairment, lateral curvature of spine, rhythmic head tremor, kyphoscoliosis, congestive heart failure (secondary to a cardiomyopathy), and lower extremity weakness. Most forms of this condition are associated with a mutation in a gene on chromosome 9, at band q13, which codes for the mitochondrial protein frataxin. (From Adams et al., Principles of Neurology, 6th ed, p1081; N Engl J Med 1996 Oct 17;335(16):1169-75) The severity of Friedreich ataxia associated with expansion of GAA repeats in the first intron of the frataxin gene correlates with the number of trinucleotide repeats. (From Durr et al, N Engl J Med 1996 Oct 17;335(16):1169-75)

Research

Studies (1)

Authors

Other Studies

1 other study available for 2,3-dimethoxy-5-methyl-6-decyl-1,4-benzoquinone and Friedreich Ataxia